Proteomic and metabolomic signatures of rectal tumor discriminate patients with different responses to preoperative radiotherapy.

ABSTRACT:

Background

Neoadjuvant radiotherapy (neo-RT) is widely used in locally advanced rectal cancer (LARC) as a component of radical treatment. Despite the advantages of neo-RT, which typically improves outcomes in LARC patients, the lack of reliable biomarkers that predict response and monitor the efficacy of therapy, can result in the application of unnecessary aggressive therapy affecting patients' quality of life. Hence, the search for molecular biomarkers for assessing the radio responsiveness of this cancer represents a relevant issue.

Methods

Here, we combined proteomic and metabolomic approaches to identify molecular signatures, which could discriminate LARC tumors with good and poor responses to neo-RT.

Results

The integration of data on differentially accumulated

SUBMITTER: Wojakowska A 

PROVIDER: S-EPMC10896604 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature